| NCT06581406 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | RECRUITING | PHASE2, PHASE3 | 2024-12-17 | 2031-10 | 2030-01 |
| NCT05733598 | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | RECRUITING | PHASE2 | 2024-08-01 | 2028-07-01 | 2027-12-01 |
| NCT06264180 | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] | RECRUITING | PHASE3 | 2024-07-11 | 2034-08-31 | 2029-01-01 |
| NCT05743270 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | WITHDRAWN | PHASE2 | 2024-01-30 | 2026-06-01 | 2026-03-01 |
| NCT05733611 | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-06-29 | 2027-03-01 | 2027-01-01 |
| NCT04735978 | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours | ACTIVE_NOT_RECRUITING | PHASE1 | 2020-12-29 | 2026-11-30 | 2026-11-30 |
| NCT04349436 | A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies | RECRUITING | PHASE1, PHASE2 | 2020-05-15 | 2028-01 | 2027-09 |
| NCT04336241 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | RECRUITING | PHASE1 | 2019-10-17 | 2028-04-30 | 2026-10-31 |
| NCT04050436 | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer | ACTIVE_NOT_RECRUITING | PHASE2 | 2019-10-08 | 2025-09 | 2025-09 |
| NCT03767348 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab | RECRUITING | PHASE2 | 2017-09-20 | 2028-12 | 2025-12 |